Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Dietary Nitrate and the Oral Microbiome in Children With Primary Hypertension

NCT07236125 · tracked via the Priya Life Science Turkey tracker
Sponsor
Yelda Kasımoğlu
Phase
Observational
Started
2026-04-15
Last updated
2026-05-08

Condition(s) studied

Primary Hypertension

Investigational drug(s) / intervention(s)

No active intervention

No active intervention: This is an observational study with no active intervention. No drug, device, behavioral, dietary, surgical, or diagnostic intervention is administered to participants. All study procedures, including oral examination, salivary sampling, pH measurement, biochemical tests, and blood pressure assessment, are non-interventional and part of standard clinical evaluation. The study only aims to observe natural variations in oral microbiota composition, nitrate-reducing activity, and blood pressure without changing participants' medical care.

Study summary

Children and adolescents with primary hypertension (high blood pressure without an underlying secondary cause) are at increased risk of cardiovascular disease in adulthood. Recent research suggests that not only the heart and blood vessels, but also the bacteria living in the mouth may play a role in blood pressure regulation. Certain oral bacteria can convert nitrate from food into nitrite and then into nitric oxide, a substance that helps blood vessels relax. If this nitrate-nitrite-nitric oxide pathway is impaired, blood pressure may rise.

This study aims to investigate the relationship between oral microbiota, salivary nitric oxide reductase activity and blood pressure in children and adolescents with primary hypertension compared with healthy peers. We will recruit participants aged 10-18 years who have a diagnosis of primary hypertension and an age- and sex-matched control group without hypertension.

All participants will undergo a non-invasive oral and dental examination and standardized blood pressure measurements. Saliva samples will be collected to measure pH, flow rate, nitrate and nitrite levels, total protein, lysozyme activity and to analyze the composition of oral bacteria using modern DNA-based techniques. Participants and/or their parents will also complete brief questionnaires about diet and general health.

No medication or dietary supplement will be given as part of the study, and no additional blood samples will be taken beyond routine clinical care. The main risk is minimal discomfort related to oral examination and saliva collection. There is no guaranteed direct benefit for participants; however, the results may help us better understand how oral bacteria and salivary nitric oxide pathways are linked to high blood pressure in young people. This knowledge may support the development of new non-invasive strategies for early detection and prevention of hypertension in the future.

Eligibility

Sex
ALL
Min age
10 Years
Max age
18 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Applied to the Istanbul University Faculty of Medicine, Department of Pediatric Nephrology, * Between the ages of 10 and 18, * Diagnosed with primary hypertension, * Clinically excluded from secondary hypertension or heart failure, * No systemic or chronic disease other than hypertension, * No periodontal disease, dental infection, or oral mucosal disease, * Not taking regular antihypertensive or other medications for a chronic disease, * Not having received antibiotic treatment in the last 3 months, * Patients who have not used mouthwash in the last 3 months, * Have no allergies to nitrate-rich foods, * Both male and female patients will be included. Exclusion Criteria: * Younger than 10 years of age or older than 18 years of age * Clinically diagnosed with secondary hypertension or heart failure * Have a systemic disease * Have periodontal disease, dental infection, or oral mucosal disease * Are taking regular antihypertensive medications or other chronic illnesses * Have received antibiotic treatment within the last 3 months * Have used mouthwash within the last 3 months * Are allergic to nitrate-rich foods will not be included in the study.

Primary outcome measure(s)

  • Microbiota Composition (16S rRNA Sequencing) — Baseline
    Characterization of bacterial community diversity and relative abundance in unstimulated saliva using 16S rRNA gene sequencing. Analysis will include alpha diversity, beta diversity, and differential taxa abundance between groups, with a focus on nitrate-reducing genera such as Neisseria, Rothia, and Actinomyces.

Trial sites (1)

FacilityCityRegionStatus
Istanbul University Faculty of Dentistry Istanbul Fatih Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07236125 on ClinicalTrials.gov ↗ ← All trials in Turkey